Guidelines prostate brachytherapy

Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy

Carl Salembier\textsuperscript{a}, Pablo Lavagnini\textsuperscript{b}, Philippe Nickers\textsuperscript{c}, Paola Mangili\textsuperscript{d}, Alex Rijnders\textsuperscript{a}, Alfredo Polo\textsuperscript{e}, Jack Venselaar\textsuperscript{f}, Peter Hoskin\textsuperscript{g,}\textsuperscript{,} on behalf of the PROBATE group of GEC ESTRO

\textsuperscript{a}Department of Radiation Oncology, Europe Hospitals, Brussels, Belgium, \textsuperscript{b}Department of Radiation Oncology, MultiMedica Institute, Milan, Italy, \textsuperscript{c}Department of Radiation Oncology, Domaine Universitaire du Sart Tilman, Liège, Belgium, \textsuperscript{d}Department of Medical Physics, IRCCS, S-Raffaele, Milan, Italy, \textsuperscript{e}Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain, \textsuperscript{f}Department of Radiotherapy, Dr B. Verbeeten Institute, Tilburg, The Netherlands, \textsuperscript{g}Mount Vernon Cancer Centre, Northwood, UK

Abstract

The aim of this paper is to supplement the GEC/ESTRO/EAU recommendations for permanent seed implantations in prostate cancer to develop consistency in target and volume definition for permanent seed prostate brachytherapy.

Recommendations on target and organ at risk (OAR) definitions and dosimetry parameters to be reported on post implant planning are given.


Keywords: Prostate cancer; LDR-brachytherapy; Seed brachytherapy; Dosimetry

Prostate cancer is an increasing health problem in Europe. The present treatment options include radical prostatectomy, external beam radiation therapy, temporary and permanent brachytherapy, hormonal therapy and watchful waiting.

In the treatment of early prostate cancer, transperineal ultra-sound guided brachytherapy using permanent implants of iodine-125 or palladium-103 has proven itself as an alternative therapy to radical prostatectomy with equivalent medium and long-term results \cite{16,32,63,65,66,70}. Since the mid-1990s, a rapid expansion of the number of permanent implants for early stage prostate cancer occurred in the USA. An identical situation is now observed in Europe \cite{11,79,80}.

Guidelines and recommendations on permanent seed implantation are available in the literature to provide a guide for those embarking on brachytherapy \cite{4,48,49}. These tend to focus on the indications for and techniques of implantation with limited attention to post implant evaluation and dosimetry. There is now a large literature on pre- and post-implant dosimetry using different techniques and modalities, but none is considered standard \cite{1,8,12,13,23,27,28,30,32,40,42,47,50,59,75}. In particular there is no consistent definition of clinical target volume (CTV), planning target volume (PTV) or defined boundaries for the organs at risk (OARs).

In some articles, the pre-implant transrectal ultrasound (TRUS) definition of the prostate is named GTV (gross tumour volume) \cite{26,54}, in others GTV (gross target volume — an acronym of ICRU terms) \cite{33}, in others CTV (clinical target volume) and in others TV (target volume) or PTV (planning target volume) \cite{44,46,69}. On the other hand, as soon as a margin is added around the “prostate contour”, the PTV (planning target volume) definition is applied, regardless of the reason or origin of this margin. For post-implant target volumes, either “prostate” or “PTV” and even a unique term “evaluated target volume” (ETV) are seen in the literature.

The ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer were published in 2000 \cite{4}. In this publication, little information is given on target (prostate gland) or organs at risk (prostatic urethra, rectum) contouring, target definition, dosimetric parameters regarding target dosimetry or dosimetric parameters regarding organs at risk. With the dramatic increase in the number of implants performed in the last five years, both in the USA and in Europe, there is an ever-increasing literature on dosimetric parameters and of clinical outcome but no common definition of the CTV, PTV or OARs. Based on an extensive review of the literature and informed by the GEC ESTRO European questionnaire results \cite{38,41} these recommendations have

0167-8140/$ • see front matter © 2007 Published by Elsevier Ireland Ltd. doi:10.1016/j.radonc.2007.01.014
been produced by the Probate Working Party of the GEC ESTRO. They have been written to harmonise and cross reference to the other guidelines produced on HDR prostate brachytherapy and those from the Gynaecology group of GEC ESTRO [29,36,60].

ICRU definitions related to LDR prostate brachytherapy

ICRU definitions [35]

Gross tumour volume (GTV). The gross tumour volume corresponds to the gross palpable, visible or clinically demonstrable location and extent of the malignant growth.

Given the TNM definition for prostate cancer, GTV can only be defined for tumour stages larger than T1c. For these tumour stages (>T1c), the GTV definition can be useful, certainly in cases where the tumour area can be identified, not only by digital rectal examination, but also by radiological examinations including transrectal ultrasound, magnetic resonance imaging and spectroscopy. In T3 disease extension through the capsule or into the seminal vesicles may be seen on imaging and included in the GTV although in general such patients will not be included in a seed brachytherapy programme.

Clinical target volume (CTV). The clinical target volume is the volume that contains the GTV and includes subclinical malignant disease at a certain probability level. Delineation of the CTV is based on the probability of subclinical malignant cells present outside the GTV.

Prostate cancer has recognised paths of microscopic spread through the capsule and into the seminal vesicles, which may occur even in very early stage prostate cancer. Probability of microscopic extension at different distances around the GTV. It is well documented in surgical literature that prostate cancer is in the majority of cases a ‘whole gland’ disease. Even in a very early stage, prostate cancer presents as a multi-focal disease — both lobes can contain microscopic disease. Given this specific behaviour, at least the whole prostate gland has to be considered as ‘target’ and included in the CTV.

Probability of subclinical invasion of the peri-prostatic tissues. When available, a magnetic resonance scan of the prostate, ideally using an endorectal coil, should be performed for radiological staging and in particular to identify those patients with T3 disease (Fig. 3) [7].

For very early stage tumours (T1c — T2) the probability of capsular penetration is related to the tumour stage (T1c <T2), iPSA and Gleason score as demonstrated in the Partin tables (Table 1) [55–57]. These tables show that even tumours with stage T1c and T2, independent of Gleason score or iPSA, have a probability of established capsular penetration of at least ten percent.

Extent of subclinical extraprostatic extension of early prostate cancer. Studies on specimens obtained by radical prostatectomy show a tendency for clinical understaging of capsular penetration, with rates ranging from 40% to 60% [10,24,52,58,73]. Only a few authors have focussed on the geometrical extent of extraprostatic disease. The largest study included 376 specimens from patients undergoing radical retropubic prostatectomy using whole organ mount examination of the extraprostatic extension (EPE) [19]. This identified EPE in 28% of examined cases. The radial EPE distance in these specimens had a mean of 0.8 mm (range 0.04—4.4 mm) and a median of 0.5 mm. Ninety-six percent of all specimens with EPE had a radial EPE distance <2.5 mm. All patients classified in the good prognostic risk group (PSA <10, Gleason <7) had a radial EPE distance <3 mm (Table 2).

Planning target volume (PTV). The PTV surrounds the CTV with a margin to compensate for the uncertainties in treatment delivery.

The PTV is a geometric concept, introduced for treatment planning. A margin must be added to the CTV either to compensate for expected physiological movements and variations in size, shape and position of the CTV during therapy (internal margin) or for uncertainties (inaccuracies and lack of reproducibility) in patient set-up during irradiation, which may be random or systematic.

Table 1
Probability of organ confined disease in very early prostate cancer (based on the Partin tables) [55]

<table>
<thead>
<tr>
<th>Gleason score</th>
<th>T1c</th>
<th>T2a</th>
<th>T2b</th>
<th>T2c</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA 2.6—4.0</td>
<td>92% (82—98)</td>
<td>85% (69—96)</td>
<td>80% (61—95)</td>
<td>78% (58—94)</td>
</tr>
<tr>
<td>2—4</td>
<td>84% (81—86)</td>
<td>71% (66—75)</td>
<td>63% (57—59)</td>
<td>61% (50—70)</td>
</tr>
<tr>
<td>5—6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA 4.1—6.0</td>
<td>90% (78—98)</td>
<td>81% (63—95)</td>
<td>75% (55—93)</td>
<td>73% (52—93)</td>
</tr>
<tr>
<td>2—4</td>
<td>80% (78—83)</td>
<td>66% (62—70)</td>
<td>57% (52—63)</td>
<td>55% (44—64)</td>
</tr>
<tr>
<td>5—6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA 6.1—10.0</td>
<td>87% (73—97)</td>
<td>76% (56—94)</td>
<td>69% (47—91)</td>
<td>67% (45—91)</td>
</tr>
<tr>
<td>2—4</td>
<td>75% (72—77)</td>
<td>58% (54—61)</td>
<td>49% (43—54)</td>
<td>46% (36—56)</td>
</tr>
</tbody>
</table>

Figure in brackets are 95% confidence intervals.
The CTV to PTV margin can be minimised in brachytherapy because there are no significant opportunities for set up error.

It is now possible to perform LDR-prostate-brachytherapy as a one-stop procedure within 60–90 min. Variation in the position of the prostate gland during implantation can be minimised using locking stabilisation needles and by the use of on-line “real-time” verification mechanisms. Later changes in the size or shape of the prostate immediately after implantation are only temporarily related to procedure-induced oedema. This oedema normally resolves within the first half-life of the radioactive seeds as shown in post-implant radiological examinations [13,22,64,81,83,86].

In prostate brachytherapy there are uncertainties in seed placement, and even here, the uncertainties can be minimised. In the original two-stage preplanned approach, seed placement uncertainty was 3 and 5 mm in the longitudinal and in the transverse directions, respectively [6,68]. Correct delivery of the seeds in an exact x/y direction can nowadays be guaranteed given the superposition of the implantation grid on the ultrasound images all through the prostate. Correct delivery of the seeds in the longitudinal (z) direction can be more difficult. Once again, available software and the correct use of continuous on-line verification of ultrasound position coupled with fluoroscopy can substantially reduce this uncertainty [12,61,76,78,87].

**Practical considerations**

The actual clinical practice in most European centres can be summarised by: (1) no use of the GTV definition (2) CTV equals the prostate gland and (3) PTV corresponds to the CTV plus a margin [38].

**Prescription and reporting — definitions and parameters**

**ICRU definitions for dose prescription**

*Gross tumour volume.* Whenever possible the GTV should be contoured on the pre-implantation ultrasound-acquired images. Where necessary, correlation with endorectal coil magnetic resonance and spectroscopy should be used.

*Clinical target volume.* The clinical target volume for pre-implant dosimetry should be the prostate gland with a margin as shown in Fig. 1 (Fig. 1).

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Dosimetry parameters for organs at risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preplan</td>
<td>Postplan</td>
</tr>
<tr>
<td>Rectum</td>
<td></td>
</tr>
<tr>
<td>$D_{2cc}$</td>
<td>$D_{2cc}$</td>
</tr>
<tr>
<td>$D_{0.1cc} \sim D_{max}$</td>
<td>$V_{100}$</td>
</tr>
<tr>
<td>$D_{10}$</td>
<td>$D_{10}$</td>
</tr>
<tr>
<td>$D_{30}$</td>
<td>$D_{30}$</td>
</tr>
<tr>
<td>$D_{5}$</td>
<td>$D_{5}$</td>
</tr>
</tbody>
</table>

**Fig. 1.** Preplanning CTV definitions. ————, prostate contour; ————, urethra prostatica; ————, clinical target volume (three-dimensional expansion of the prostate — 3 mm in each direction); ————, clinical target volume constrained to the anterior rectal wall (three-dimensional expansion of the prostate — 3 mm in each direction BUT 0 mm in the posterior direction).

**Fig. 2.** Post-plan definitions of CTV. Legend: ————, CTV-P = CTV-prostate; ————, CTV-PM = CTV-prostate margin; ————, urethra prostatica; ————, rectum (outer and inner wall).

For **T1** — **T2** prostate cancer the CTV corresponds to the visible contour of the prostate expanded with a three-dimensional volume expansion of 3 mm.

This three-dimensional expansion can be constrained to the anterior rectal wall (posterior direction) and the bladder neck (cranial direction).

For **T3** tumours, the CTV corresponds to the visible contour of the prostate including visible extension due to extracapsular growth which is then expanded with
a three-dimensional expansion of three millimetres in each direction, with rectal and bladder constraints as above.

**Planning target volume.** Using online in vivo 3-D dosimetry and fluoroscopy in addition to sonography to eliminate errors due to seed placement, there is no need for an expansion from the CTV to define the PTV, i.e., PTV = CTV.

**Organs at risk.** Different organs at risk can be defined in the pre-implantation setting [4,15,82,87].

(a) Prostatic urethra: common practice to obtain visualisation of the urethra is to use a urinary catheter. This should be a small gauge catheter, French gauge 10, to avoid distension of the urethra. The surface of the catheter is used to define the urethral surface from the prostatic base to apex. However in practice the urethra is not a circular structure and an alternative which may give a more accurate anatomical picture is to instil aerated gel into the urethra prior to obtaining the ultrasound images.

(b) Rectum: using transrectal ultrasound, visualisation of the anterior rectal wall is no problem but may introduce artefacts due to displacement and distension. Many simply outline the outer wall and this should be regarded as the minimum requirement; others define outer and inner walls to define a doughnut as shown in Fig. 1. In terms of the critical cells in the rectum for late damage the latter is probably more correct. For defining small volumes up to 5cc outlining the outer wall alone is therefore sufficient. This is in keeping with the recommendations in the Gynaecology recommendations.

(c) Penile bulb and/or neurovascular bundles: currently this remains investigational.

**Recommended prescription doses**

The AAPM-TG-64 recommendations are universally implemented [80,85]. The standard dose to the 100% isodose is 145 Gy for low dose rate 125I seeds and 125 Gy for 103Pd. (NIST 99) [51,67,84].

**Dosimetric parameters related to ICRU definitions for dose prescription**

**Gross tumour volume.** The GTV should be encompassed by the 150% isodose.

**Clinical target volume (equals planning target volume).** Physical parameters correlating with a good pre-implantation dosimetry:

- The \( V_{100} \) (the percentage of the CTV that receives the prescribed dose) must be at least 95% \( (V_{100} \geq 95\% \text{ of } \text{CTV}) \).
- Therefore, the \( D_{90} \) (the dose that covers 90% volume of the CTV) will be larger than the prescription dose \( (D_{90} > 100\% \text{ of prescription dose}) \).
- The \( V_{150} \) (the percentage of the CTV that receives 150% of the prescription dose), should be equal to or less than 50% \( (V_{150} \leq 50\% \text{ of } \text{CTV}) \).

**Organs at risk.**

(a) Rectum:

- Primary parameter: \( D_{2cc} \leq \) reference prescription dose of 145 Gy.
- Secondary parameter: \( D_{0.1cc} (\sim D_{\text{max}}) < 200 \text{ Gy} \).

it is recommended in common with the other published guidelines that the dose to a very small limited volume (0.1 cm³) is more appropriate for dose calculation clinical relevance than a maximal dose value [60].

(b) Prostatic urethra:

- Primary parameter: \( D_{10} < 150\% \text{ of the prescription dose} \).
- Secondary parameter: \( D_{30} < 130\% \text{ of the prescription dose} \).

(c) Penile bulb and neurovascular bundles:

Investigational at present, no parameters can be reliably defined.

**Physical parameters for dose reporting**

All implants should undergo post implant evaluation. This should be based on imaging at 4–6 weeks after implantation at which time initial oedema will have settled. Optimal imaging will include MRI but if not available CT alone is adequate.

This ensures good quality control of the implant process and there is now good evidence that the probability of achieving biochemical control is related to the quality of the implant. This can only be evaluated by detailed post-implant dosimetry [74,75,86].

**Post-planning — definitions and parameters**

**Theoretical considerations**

The ESTRO-EAU-EORTC guidelines for post-implant evaluation recommend CT-imaging [4]. Image registration with MRI may improve the definition of the CTV for evaluation and decrease the inter-observer variability but CT remains the best means of seed identification [2,13,14,20,23,27,28,30–32,39,40,42,43,47,59,62,74,77].

**Seed evaluation.** A critical step in post-implant dosimetry is the identification of the seeds in the target region. There is a small risk of seed loss or seed migration. Depending on the implantation technique and on the type of seeds used (loose seeds versus stranded seeds), the migration rates vary between 1% and 15% [9,17,18,25,26,34,37,45,53,72]. For post-implant purposes, the exact number and position of seeds in the target area must be known.

Because the sources appear on more than one CT-slice, a seed location method (seed sorting) based on nearest neighbours needs to be employed. Software algorithms have been developed to find seeds, but the exact number of seeds in the prostate at the time of evaluation is required. All patients should therefore undergo imaging with either plain X-rays of the implanted zone to allow accurate counting with two films at different angles to iden-
tify superimposed seeds. This could also be obtained using
CT scout views (topogram). If there are missing seeds, particularly where loose seeds are used a chest X-ray is also recommended.

Once the actual number of seeds in the target area is known, introduction of the number of seeds into the treatment planning system allows localisation of the seeds by the automatic seed finder option. Seed position detection can be performed on either CT or MRI slices. Using CT, scatter around the seeds can complicate this evaluation, but the use of specific filters during the CT-examination may decrease this scatter. On MRI, the seeds are seen as black holes in the organ and individualisation of the different seeds may be more difficult. Some centres prefer the use of ultrasound based post-implant evaluation to define seed positions. The lack of clear visualisation and individualisation of the implanted seeds remains a major problem; developments in seed technology, with more echogenic ‘smart’ seeds, may aid this process.

Recently two dedicated phantoms for CT and MRI were developed to perform quality assurance of the seed reconstruction procedure [21,71].

Prostate and organ at risk contouring. The accurate contouring of the prostate and organs at risk is essential for useful post implant dosimetry. Several studies have noted discrepancies in volume of the prostate as determined by TRUS, CT and MRI, reflecting the difficulties in differentiating the prostate from the periprostatic muscle and venous plexus using CT. Greatest variations are seen in defining the base and apex of the gland. Whilst CT is the most valuable option for seed positioning, MRI is the most valuable option for organ contouring [2,3,5,13,20,22,43,47,59]. An additional problem is the degree of inter-observer variability in the definition of the prostate volume on post-implant CT and MRI images [1,14,31,40,42]. Close interaction with diagnostic radiologists and training are essential to maximise the potential of the available imaging modalities.

Target definition in relation to the post-plan
dosimetry

General considerations. As in the pre-plan situation, a multitude of different definitions are in use. Classical ICRU terms as CTV and PTV, but also terms as ETV (evaluated target volume), are frequently seen in reports on post-implant dosimetry. The exact definition is seldom given and is left to the interpretation of the reader.

Target definitions. Post-implant it is almost always impossible to define a GTV on the radiological images due to interference from the seeds.

CTV and PTV definitions remain the same as stated in Clinical target volume/Planning target volume.

Two different CTV definitions are proposed as shown in Fig. 2.

(a) CTV-P( prostate) = the post-implant contour of the prostatic gland defined by the capsule on radiological examination.

(b) CTV-P(rostate)M(argin) = the post-implant contour of the prostatic gland defined by the capsule with a three-dimensional expansion of 3 mm.

Organs at risk. The only OAR that can be reliably defined both on CT and MRI is the rectum. For contouring purposes, using CT only the outer rectal wall can be reliably defined; using MR the outer and inner walls of the rectum over the whole region of interest may be indicated. The lower rectum is poorly defined on CT and best shown with MRI. Image fusion techniques may therefore be of value. However, there is no consistent definition of the rectal volume to be outlined.

The definition of the prostatic urethra is poor on CT and MRI and can only be accurately achieved when a urinary catheter or aerated gel is introduced during post-implant scanning. The recent European questionnaire study [38,41] shows that this is seldom performed. Correlation with or formal fusion of TRUS images with the obtained CT- or MR images may be the optimal non-invasive technique for localisation of the urethra on the post implant scan. Institutional policy should be described if urinary parameters are published.

Defining the penile bulb and neurovascular bundles is only possible with accuracy on MRI.

Dose parameters in the post-implant setting

Target volumes. The primary parameters – D90, V100 and V150 – should always be reported for both CTV-P and CTV-PM.

Secondary parameters – V200, D100, natural dose rate (NDR), homogeneity index (HI) and conformal index (CI) may also be reported although their value in relation to outcome is not proven and should be a focus for further research.

Organs at risk. D2cc for the rectum and D50 for the urethra are at present the primary parameters.

Secondary parameters, D0.1cc and V100 for rectum and D0.1cc, D30 and D5 for urethra, may also be reported. Volume (V) parameters should be expressed in absolute values (cc).

No parameters can be given at present regarding penile bulb and neurovascular bundles. Further investigation and evaluation is needed.

Conclusions

These recommendations should be considered in conjunction with the ESTRO/EAU/EORTC recommendations on permanent seed implantation for localised prostate cancer which were published in 2000. This guidance was, as noted in the paper, intended for those embarking on brachytherapy to identify the factors related to successful outcome but did not focus on target (prostate gland) or organ at risk (prostatic urethra, rectum) contouring, target definition, dosimetric parameters regarding target dosimetry or dosimetric parameters regarding organs at risk, which is the object of this second publication.
References


[38] Lavagnini P, Mangili P, Venselaar J. Recommendations of the Brachyphys Prostate Sub-Group, the clinical part of the questionnaire. Radiother Oncol 2005;75:S22, abstract 49.


Prostate brachytherapy guidelines


